Opus Genetics says FDA aligns on Phase 3 trial design for OPGx-LCA5 gene therapy in LCA5 retinal disease

Opus Genetics, Inc.

Opus Genetics, Inc.

IRD

0.00
  • Opus Genetics reached FDA alignment on a registrational Phase 3 trial design for OPGx-LCA5 in LCA5-associated inherited retinal disease.
  • FDA indicated a BLA could be filed on 6-month efficacy data, with 12-month durability data submitted during review.
  • Phase 3 targets eight participants with a six-month run-in natural history control; seven are already enrolled.
  • Primary endpoint targets at least 7 dB mean improvement in retinal sensitivity; trial designed for more than 90% power.
  • Phase 3 dosing is expected to start in 4Q 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief on July 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.